Objectives: Gastric cancer (GC) is one of the most common cancers in the world, causing a large number of deaths every year. The Slit-Robo signalling pathway, initially discovered for its critical role in neuronal guidance, has recently been shown to modulate tumour invasion and metastasis in several human cancers. However, the role of Slit-Robo signalling and the molecular mechanisms underlying its role in the pathogenesis of gastric cancer remains to be elucidated.
| INTRODUC TI ON
Gastric cancer (GC) is the third leading cause of cancer-related death and responsible for approximately 723 000 deaths worldwide every year.
1 Nearly half of the cases occur in Eastern Asia and are mostly diagnosed at the advanced stage. 2 As a consequence, the 5-year survival rate for advanced GC patients remains at only 5%-20%. Hence, it is critical to explore the molecular mechanisms of GC development for finding new treatment strategy of GC.
Slit glycoproteins (Slit1-3), originally discovered as neuronal guidance cues, are secreted by midline glia 4 that exert their function by binding to single-pass transmembrane proteins Roundabout family (Robo1-4). 5-7 The Slit-Robo signalling pathway plays important roles not only in neuronal guidance but also during cell migration of a wide range of cell types. [6] [7] [8] [9] [10] Recent studies indicate that the inactivation of this pathway is associated with the progression of several cancer types, [11] [12] [13] including pancreatic cancer, 14 breast cancer, 15 as well as lung tumours. 16 However, the precise function of the Slit-Robo pathway in the development of GC remains ill-defined. A number of studies supported the notion that Slit-Robo signalling plays an important role in anti-tumour processes. 17, 18 In contrast, two other reports suggested that Robo1 might promote tumorigenesis. 19, 20 Ubiquitin-specific protease 33 (USP33), a member of ubiquitinspecific protease family, was initially identified as a substrate molecule which binds to VHL E3 ligase. 21 Previous studies showed that USP33 is a Robo1-interacting protein that is involved in Slit signalling in midline axons crossing. 22 Furthermore, USP33 is required for SlitRobo signalling in inhibiting breast cancer cell migration. 15 Together, these studies demonstrate that USP33 plays an important role in the Slit-Robo pathway.
Recently, a study based on data from one patient cohort reported that USP33 expression was found to be reduced in GC and that reduced USP33 expression was associated with poor prognosis. 23 However, the precise molecular mechanisms of how USP33
exerts the anti-tumour function in GC remain to be elucidated.
Here, we set out to investigate the role of Slit-Robo signalling and the precise molecular mechanisms of how USP33 affects the Slit-Robo signalling in GC.
| ME THODS

| Clinical samples and cell culture
Primary GC samples were obtained from 54 and incubated in a humidified chamber at 37°C under 5% CO 2 .
| Antibodies and reagents
Anti-Robo1 (ab7279), anti-USP33 (ab71716), anti-E-cadherin (ab1416),
anti-vimentin (ab8978) and anti-GAPDH (ab8245) were purchased from Abcam (USA). Anti-Flag (F3165) and cycloheximide (CHX, C7698)
were obtained from Sigma-Aldrich (USA). MG132 (HY-13259) and chloroquine (HY-17589) were obtained from MedChemexpress (USA).
| RNA interference, plasmids and lentivirus transfection
The small interference RNA targeting USP33 (#1:5′-GGAGAAUAGAUGUUCAUAUTT-3′; #2:5′-GCUGCAUUCAUCAAG   UCAUTT-3′) and a control siRNA (5′-TTCTCCGAACGTGTCA CGTTT-3′) were purchased from Gene Pharma Biotech (Shanghai, China). The lentiviral vector containing USP33 siRNA hairpin sequence and the puromycin resistance sequence (LV-shUSP33) was also constructed by Gene Pharma. Slit2 tagged with c-myc plasmid was generated as previously described. 7 SiRNA and plasmids were transfected using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's instructions.
| RNA extraction and qRT-PCR analysis
Total RNA was extracted from cells or frozen tissues with TRIzol reagent (Invitrogen), and then cDNA was synthesized using PrimeScript RT Master Mix kit (RR036A; Takara). The PCRs were then performed using the 7500 Real-Time PCR System (Applied Biosystems, USA) with the primers as follows: Slit2 forward, 5′-ACCGCTTCCAGTGCAAAGTA-3′, reverse, 5′-CTGGGTGCATGTCC CGTTAT-3′; Robo1 forward, 5′-GCATCCTCTCTGCCCTTCTC-3′, reverse, 5′-CTGGCTCGTGGAAGCTGTA A-3′; USP33 forward, 5′-AAAAT   CCCTTGGTACTTGTCAGG-3', reverse, 5′-TCGAAGAGTGGTAAGGTT   CACA-3′; and GAPDH forward, 5′-AGAAGGCTCATTTG-3′, reverse, 5′-AGGGGCCATCCACAGTCT TC-3′.
| Wound-healing assay
Cell migration was examined in a modified wound-healing assay. 
| Transwell assay
To 
| Western blot and immunoprecipitation
Total protein lysates were prepared with a protein extraction kit (KGP9100, Key Gene). Proteins were separated on 10% gels by SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. After blocking in 5% non-fat milk in TBST buffer, the membranes were incubated with specific primary antibodies at 4°C overnight and followed by secondary antibodies. The signals were visualized using the chemiluminescence HRP substrate (WBKL0100; Millipore) and a chemiluminescence detection system.
Cell lysates were used for immunoprecipitation using the Dynabeads Protein G Immunoprecipitation kit (Invitrogen) following the manufacturer's guidelines. Immunoprecipitated proteins were then detected by Western blot.
| Immunohistochemical analysis
All specimens were fixed in 4% formalin and then embedded in paraffin. The 4 μm sections were incubated with primary antibodies at 4°C
overnight. After washing with PBS, the sections were incubated with HRP-polymer-conjugated secondary antibody at room temperature for 1 hour. Next, sections were stained with DAB solution for 3 minutes and the nuclei were counterstained with haematoxylin. The results were evaluated by both the intensity of cell staining (graded as 0, no staining; 1, weak; 2, moderate; and 3, strong) and the percentage of positive tumour cells (graded as 0, <5%; 1, 5%-25%; 2, 26%-50%; 3, 51%-75%; and 4, >75%). Intensity score and percentage score were calculated.
| Immunofluorescence microscopy
Cells were cultured on collagen-coated glass coverslips for 24 hour 
| Statistical analysis
All data were analysed using SPSS 20.0 software (SPSS Inc, Chicago, IL, USA). The results obtained from cell line experiments and animal assays were analysed using Student's t test (for two groups)
or ANOVA (for more than two groups). Mann-Whitney U test was used to analyse differences in immunohistochemical (IHC) scores.
Chi-square test was used to analyse association of the expression of Robo1 and USP33 with clinicopathologic features. The KaplanMeier method was used the survival analyses. The optimal cut-off F I G U R E 2 Slit2 inhibits migration of GC cells in a Robo-dependent manner and suppresses EMT markers. A, Cell migration was examined in a wound-healing assay using MGC-803 cells in the medium containing the mock control (Ctrl), Slit2 The expression of epithelial cell marker (E-cadherin), mesenchymal cell markers (N-cadherin, Vimentin) and related transcription factors (Snail, Slug) was analysed by Western blotting. GAPDH was used as an internal control. All data are shown as mean ± SEM and analysed by Student's t test, *P < 0.05, **P < 0.01, ***P < 0.001
values of USP33 expression were generated by X-tile software. Data are presented as the mean ± SD. P < 0.05 was considered significant.
| RE SULTS
| Expression of Slit2 and Robo1 is downregulated in gastric cancer
To investigate the role of Slit-Robo family in GC, we first measured Slit2, 3 and Robo1, 2, 3 expression in 54 paired cancer tissues and matched adjacent non-cancer tissues from GC patients.
Slit1 was excluded for its limited expression in nervous tissues, and
Robo4 was excluded for lacking of Slit binding site. It was found that Slit2 and Robo1 showed the most significant decrease in GC Both mRNA and protein levels of Robo1 in GC cell lines were found to be lower than those determined for GES-1.
| Slit2 inhibits GC cell migration in a Robodependent manner and suppresses EMT
To investigate the role of Slit2-Robo1 signalling in GC progression, we used two independent GC cell lines, MGC-803 and BGC-823 expressing Robo1 receptor for the following studies ( Figure 1H ). We 
It is well documented that epithelial-mesenchymal transition
(EMT) is a critical process in cell invasion and metastasis. 25, 26 We first examined the epithelial marker E-cadherin and the mesenchymal marker vimentin by Western blot and immunohistochemistry in GC samples. Compared with the normal tissues, E-cadherin protein levels were lower in GC samples, while vimentin levels were found to be elevated (see Figure S1D -H).
To examine the potential role of Slit2 signalling in EMT of gas- Together, these results clearly demonstrated that Slit2 inhibits GC cell migration and invasion in a Robo-dependent manner and suggest that Slit2 signalling suppresses EMT in GC.
| USP33 expression is down-regulated in GC and correlates with Robo1 expression
Our previous studies suggested that USP33 regulates the expression of Robo1 and is therefore essential for the activation of the Slit-Robo pathway. 15, 27, 28 The observation that Robo1 expression is reduced in GC samples prompted us to examine whether USP33 affects the development of GC.
Analysis of USP33 expression in the public GC datasets showed that USP33 is commonly down-regulated in GC samples Figure 3A,B) . We further examined the USP33 mRNA expression in our own cohort of paired GC samples. Unsurprisingly, USP33 mRNA expression was also found to be lower in GC tissues ( Figure 3C ).
Moreover, linear regression analysis revealed that the relative expression levels of USP33 correlated well with Robo1 ( Figure 3D ).
USP33 protein levels were also reduced in GC tissues by both immunohistochemistry and Western blot analysis ( Figure 3E -G).
Consistently, both mRNA and protein levels of USP33 were lower Figure 3H,I ).
To assess the overall frequency of genetic alterations of USP33 in GC patients, we analysed large datasets from cBioPortal for Cancer Genomics (http://cbioportal.org). 29 As shown in Figure 3J , mutations of the USP33 gene in GC patients were detected in five independent cohorts, ranging from 1% to 4.55%, while copy number alteration (CNA) was observed in three cohorts. Interestingly, ten USP33 mutations were identified in GC patient samples, with five mutations inside the catalytic domain of USP33 and two additional frameshift (fs) mutations upstream of the catalytic domain ( Figure 3K ).
| USP33 interacts with Robo1 in GC cells
To examine the relationship between USP33 and Robo1, we transfected MGC-803 and BGC-823 with two different siRNAs against USP33 (siUSP33 #1 and #2). Quantitative RT-PCR analysis showed that the USP33 siRNAs reduced mRNA expression of USP33
( Figure 4A ). Robo1 mRNA levels, however, were not affected by USP33 siRNAs ( Figure 4B ). In comparison, Western blot showed that USP33 knock-down caused a decrease in both USP33 and Robo1 protein levels ( Figure 4C ), suggesting that USP33 regulates Robo1
protein expression through post-translational modification.
We next examined whether USP33 interacts with Robo1 in GC cells by co-immunoprecipitation assay. While the control antibody
showed no precipitation, the anti-Robo1 antibody specifically co- (see Figure S2A ).
| USP33 deubiquitinates and stabilizes Robo1
We next examined whether USP33 affects the stability of Robo1.
MGC-803 cells were transfected with either siUSP33 or control siRNA (Ctrl), and treated with cycloheximide (CHX, an inhibitor of protein synthesis). We then performed a time-course experiment to measure the protein levels as a function of time. As shown in The main proteolytic systems responsible for intracellular protein degradation are the ubiquitin-proteasome system (UPS) and the lysosomal system. 30 To examine the role of lysosomes vs the UPS system in Robo1 degradation, MGC-803 cells were treated with chloroquine (CHQ, a lysosome inhibitor) or MG132 (a proteasome inhibitor). The Robo1 protein level increased after MG132 treatment, whereas chloroquine treatment failed to show visible effects ( Figure 4G ). These effects were also confirmed in additional 4 GC cell lines (see Figure S2B ), suggesting that Robo1 is degraded mainly via the ubiquitin-proteasome system in GC cells.
Furthermore, the decrease in the Robo1 protein level induced by siUSP33 was blocked by MG132 ( Figure 4H ). We then examined the levels of ubiquitinylated Robo1 after co-transfecting Flag-tagged ubiquitin (Flag-Ub) together with either control siRNA (Ctrl) or siUSP33. Downregulation of USP33 increased the level of ubiquitinylated Robo1 in the presence of MG132 ( Figure 4I ).
Together, these data support the notion that USP33 stabilizes Robo1, preventing it from ubiquitin-proteasome-mediated degradation.
| USP33 mediates Slit2 signalling in inhibiting GC cell migration and EMT process in vitro
To test the involvement of USP33 in Slit2-Robo1 signalling, we per- 
| USP33 mediates the inhibitory function of Slit2 signalling on metastasis in vivo
To investigate the role of Slit2 and USP33 in GC metastasis, we used an in vivo xenograft model. Control MGC-803 or BGC-823 cells, cells stably co-expressing Slit2 with shControl or shUSP33 were injected into the caudal veins of athymic BALB/c nude mice (6 mice per group).
Mice were monitored for 6 weeks using an IVIS Imaging system. Six Together, these results strongly suggest that USP33 mediates Slit2 signalling in inhibiting GC metastasis in vivo.
| USP33 is required for Slit2-Robo1 signalling in inhibiting TGF-β pathway
To further elucidate the potential pathway regulated by Slit2-Robo1 signalling, a gene set enrichment analysis was performed using Slit2 expression as a phenotype label in GC cohorts from TCGA database.
Higher Slit2 expression was significantly correlated with negative regulation of TGF-β pathway and pathway that restricted Smad protein phosphorylation (P < 0.05; Figure 6E ,F). Transforming growth factor-β (TGF-β) is widely upregulated in several human cancers 31 and could promote invasion and metastasis by inducing EMT in cancer cells, 32 while the phosphorylation of Smad proteins plays a key role in the TGF-β pathway. 33 These data suggested that Slit2 may inhibit migration and EMT via inhibiting TGF-β pathway in GC.
We then measured the key proteins involved in TGF-β pathway.
Western blot showed that Slit2 reduced the expression of TGF-β receptor I (TGFBR1), p15 (a downstream target of TGFβ), Smad2 and Smad4 in MGC-803 and BGC-823, while these effects were attenuated by USP33 knock-down ( Figure 6G ).
These results indicated that USP33 is required for Slit2-Robo1 signalling in inhibiting TGF-β pathway.
| USP33 expression is inversely correlated with tumour size, lymph node metastasis and neural invasion in GC, and low USP33 expression predicts poor survival
To explore the clinical significance of USP33, we examined the correlation between the USP33 expression and clinicopathological characteristics in our GC cohort. As shown in Table 1, USP33 expression was inversely correlated with tumour size, lymph node metastasis and neural invasion. From TCGA dataset, higher USP33 expression significantly correlates with longer overall survival ( Figure 6H ). Furthermore, KM-plotter analysis of additional GC datasets 34 also shows that high USP33 expression was associated with extended patient survival in two independent datasets, GSE62254
and GSE15459 ( Figure 6I,J) . Together, these results suggest that USP33 represents a suitable choice as a prognostic marker for GC.
| D ISCUSS I ON
Gastric cancer remains a common cause of tumour-related death and a major health problem in the world, especiallyin Eastern Asia.
1,2
Although great efforts have been made, the mechanisms underlying the tumorigenesis and development of GC remain implicit, which partially accounts for the poor prognosis of GC patients. Epithelial-mesenchymal transition (EMT) has emerged as a critical process of cell invasion and metastasis in most epithelial tumour, including GC, 25, 26 and could serve as a potential target for cancer pharmacological intervention. 35 In this study, we first report the involvement of Slit-Robo signalling in the EMT of GC. We also demonstrate the mechanism of how USP33 mediates Slit-Robo signalling in GC. As illustrated in Figure 7 , USP33 interacts with Robo1 and stabilizes Robo1, preventing it from ubiquitin-proteasome-mediated degradation.
The first indication that Slit-Robo signalling might play an important role in cancer derived from studies by Sundaresan and colleagues, which identified and cloned the DUTT1 gene (later renamed as ROBO1) and used probes to detect two homozygous deletions at the 3p12 locus in lung and breast carcinomas. 36, 37 Subsequent studies have confirmed the involvement of Slit-Robo signalling in several types of cancer. 14, 17, [38] [39] [40] Overwhelming evidence suggests that Slit expression is reduced in different types of cancers.
38,39
However, the role of Slit-Robo signalling in GC remains controversial.
For example, it was reported that POU2F2 promotes GC metastasis through a positive regulation of Robo1, 19 whereas another study showed that down-regulating Slit2 increases growth and motility of GC cells by activating AKT/β-catenin. 17 In our study, we clearly demonstrate the downregulation of Slit2 and Robo1 expression in multiple datasets and our samples at both mRNA and protein levels. Our data indicate that Slit2 inhibits the migration of GC cell in a Robo-dependent manner. This is consistent with our previous studies of lung cancer 16 and breast cancer 15 and with other studies such GAPDH was used as an internal control. All data are shown as mean ± SEM and analysed by Student's t test, *P < 0.05, **P < 0.01, ***P < 0.001 as medulloblastoma 43 and glioma. 44 Moreover, we found that Slit2 inhibits the EMT process, which may support for the clinical application of Slit-Robo signalling.
Several Robo-interacting molecules, such as srGAP, 49 The findings of these studies suggest that USP33 possesses biological functions critical for a wide range of human physiological and pathological processes.
As a Robo1-interacting protein, our previous studies have demon- Chi-square test was performed to analyse the correlations, *P < 0.05.
TA B L E 1
Correlation between USP33 mRNA expression and the clinicopathological characteristics in 54 paired GC patients F I G U R E 6 USP33 mediates the inhibitory function of Slit2 signalling in GC metastasis in vivo, and low USP33 expression predicts shorter patient survival. (A) MGC-803 cells stably expressing Slit2, Sli2 + shUSP33 or the control (1 × 10 6 cells in 100 μL PBS) were injected into the tail vein of 4-week-old female BALB/c nude mice (6 mice per group). Tumour progression and metastases were monitored using an IVIS Imaging system. Mice were euthanized 6 weeks after injection, and the lung tissues were harvested for haematoxylin-eosin (HE) staining. cancer cell migration and EMT. To our knowledge, it is the first study investigating the molecular mechanisms of USP33 in GC.
Transforming growth factor-β (TGF-β) has been proved as a critical factor during malignant progression in many types of cancer; meanwhile, the increased level and tumour-promoting function of TGF-β in gastric cancer have also been reported. 50, 51 Furthermore, TGF-β signalling is closely related to EMT and contributes to distant metastatic of tumours 32, 53 and Smad protein phosphorylation is a key step during the activation TGF-β signalling. 54, 55 In this study, by the gene set enrichment analysis and Western blot of the key proteins, we demonstrated that the inhibitory functions of Slit2-Robo1 on cell migration and EMT are mediated partially by the inactivation of TGF-β signalling and USP33 is required for these effects.
The degradation of many intracellular short-lived proteins relies on the ubiquitin-proteasome system (UPS). 56 The therapy targeting the ubiquitin system has developed into a promising strategy for cancer treatment. 57 Data from our patient samples together with analyses of multiple independent datasets show that higher USP33
expression is significantly associated with longer patient survival,
suggesting the potential applications of USP33 for GC therapy and predicting prognosis. Future studies are needed to investigate the potential value of Slit2-Robo1-USP33 in diagnosis and treatment of GC.
In summary, our data reveal the new molecular mechanism of USP33 in GC and Slit2-Robo1-USP33 pathway in suppressing GC cell migration and EMT. In addition, higher USP33 expression is significantly associated with extended patient survival. These results support the suppressive role of USP33 in GC and suggest the potential of USP33 as a prognostic biomarker and therapeutic target for GC.
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